7cae81e814
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
49 lines
No EOL
1.7 KiB
Markdown
49 lines
No EOL
1.7 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: protocol
|
|
name: Wegovy Oral (Oral Semaglutide)
|
|
parent_company: Novo Nordisk
|
|
status: FDA approved
|
|
domain: health
|
|
---
|
|
|
|
# Wegovy Oral (Oral Semaglutide)
|
|
|
|
**Type:** GLP-1 receptor agonist, oral formulation
|
|
**Manufacturer:** Novo Nordisk
|
|
**Status:** FDA approved January 2026
|
|
**Indication:** Weight management in adults with obesity or overweight + ≥1 comorbidity; cardiovascular risk reduction in adults with CVD + obesity/overweight
|
|
|
|
## Overview
|
|
|
|
First oral GLP-1 receptor agonist approved for weight management. Eliminates injection barrier that limited injectable semaglutide (Wegovy) adoption.
|
|
|
|
## Clinical Evidence
|
|
|
|
**OASIS 4 Trial (Phase III):**
|
|
- Duration: 64 weeks
|
|
- Population: n=307
|
|
- Primary endpoint: Weight loss 16.6% (treatment) vs 2.7% (placebo) with reduced calorie diet + exercise
|
|
- Safety: Serious adverse events 3.9% (treatment) vs 8.8% (placebo)
|
|
- Common adverse reactions: nausea, vomiting, diarrhea (standard GLP-1 class profile)
|
|
|
|
## Regulatory Status
|
|
|
|
**FDA Label (January 2026):**
|
|
- Boxed warning: Thyroid C-cell tumor risk (standard GLP-1 class warning)
|
|
- NO eating disorder warning or screening requirement
|
|
- Suicidal behavior/ideation warning REMOVED in 2026 review (no causal link found)
|
|
- No contraindications for psychiatric comorbidity or eating disorder history
|
|
|
|
## Market Significance
|
|
|
|
Oral formulation expands addressable GLP-1 population by eliminating injection barrier. Accelerates trajectory toward mass-market adoption (1-in-8 Americans forecast).
|
|
|
|
## Manufacturing
|
|
|
|
Novo Nordisk North Carolina facilities.
|
|
|
|
## Timeline
|
|
|
|
- **2026-01-01** — FDA approval for weight management and cardiovascular risk reduction
|
|
- **2026-01-01** — Launch with North Carolina manufacturing capacity |